Newman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc.
May 15 2017 - 9:00PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Kite Pharma Inc.
(“Kite” or the “Company”) (NASDAQ:KITE) into potential breaches of
fiduciary duty by the Company’s Board of Directors (the
“Board”).
Kite, headquartered in Santa Monica, CA, is a clinical-stage,
biopharmaceutical company focused on cancer immunotherapy products.
Newman Ferrara’s investigation focuses on decisions made by the
Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the
Company. Considering the Company’s lackluster performance since its
2014 initial public offering, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current Kite stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com)
to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170515006534/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Sep 2024 to Oct 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Oct 2023 to Oct 2024